Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Bevacizumab + mFOLFOX7 in Stage II-III Rectal Cancer
NCT01871571Phase 2Terminated
- Sponsor
- University of Southern California
- Start
- Aug 2013
- Primary completion
- Mar 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in rectal cancer, sponsored by University of Southern California. Started Aug 2013; status: terminated.
02
Drugs
bevacizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT01871571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01871571.